Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Scheduled to Post Earnings on Tuesday
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) is scheduled to be releasing its earnings data after the market closes on Tuesday, August 8th. Analysts expect Jazz Pharmaceuticals PLC to post earnings of $1.85 per share for the quarter. Jazz Pharmaceuticals PLC has set its FY17 guidance at $10.70-11.30 EPS.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last released its earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported $1.41 EPS for the quarter, missing analysts’ consensus estimates of $1.42 by $0.01. Jazz Pharmaceuticals PLC had a return on equity of 24.65% and a net margin of 26.28%. The business had revenue of $376.10 million for the quarter, compared to analyst estimates of $376.58 million. During the same period in the prior year, the firm posted $2.26 EPS. Jazz Pharmaceuticals PLC’s revenue was up 11.9% on a year-over-year basis. On average, analysts expect Jazz Pharmaceuticals PLC to post $7.29 EPS for the current fiscal year and $8.84 EPS for the next fiscal year.
In other Jazz Pharmaceuticals PLC news, CEO Bruce C. Cozadd sold 30,000 shares of the firm’s stock in a transaction on Thursday, May 11th. The shares were sold at an average price of $153.47, for a total value of $4,604,100.00. Following the completion of the sale, the chief executive officer now directly owns 296,418 shares in the company, valued at $45,491,270.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael Patrick Miller sold 200 shares of the firm’s stock in a transaction on Monday, May 15th. The stock was sold at an average price of $152.98, for a total transaction of $30,596.00. Following the completion of the sale, the executive vice president now owns 22,623 shares of the company’s stock, valued at $3,460,866.54. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 43,100 shares of company stock valued at $6,645,820. 4.30% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: “Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Scheduled to Post Earnings on Tuesday” was published by Daily Political and is owned by of Daily Political. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://www.dailypolitical.com/2017/08/07/jazz-pharmaceuticals-plc-nasdaqjazz-scheduled-to-post-earnings-on-tuesday.html.
Several equities analysts have recently issued reports on the stock. BidaskClub downgraded shares of Jazz Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a research note on Thursday. BMO Capital Markets raised their price target on shares of Jazz Pharmaceuticals PLC from $192.00 to $196.00 and gave the company an “outperform” rating in a research note on Wednesday, June 7th. Janney Montgomery Scott raised their price target on shares of Jazz Pharmaceuticals PLC from $138.00 to $175.00 and gave the company a “buy” rating in a research note on Tuesday, July 4th. Leerink Swann raised their price target on shares of Jazz Pharmaceuticals PLC from $169.00 to $170.00 and gave the company a “buy” rating in a research note on Tuesday, July 4th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and set a $182.00 price target on shares of Jazz Pharmaceuticals PLC in a research note on Wednesday, June 7th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eighteen have given a buy rating to the stock. Jazz Pharmaceuticals PLC has a consensus rating of “Buy” and an average price target of $182.56.
About Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.